HIMS Hims & Hers Health, Inc.

QT34

NYSE·Healthcare·Medical - Care Facilities·USA

Latest market price

25.24

-2.44-8.81%

Overview Short InterestFilings

HIMSQT34Hims & Hers Health, Inc.·NYSE

Overview Short InterestFilings

25.24-8.81%

News

Down 8.8% — Can Hims & Hers Stock Rally 50% After This Dip? (Yahoo).

Medium confidence

Loading chart...

Signal & projected range

Insider open-market saleHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

CON-0.12%$40.33 LFST-1.04%$13.26 OPCH-0.44%$31.69 CHE+1.40%$542.18 PACS-4.66%$45.58 UHS+2.61%$180.65 NHC-1.96%$202.09 ENSG-1.36%$179.06

Snapshot

Index	—	P/E	—	EPS (ttm)	-0.63	Insider Own	3.19%	Shs Outstand	224.94M	Perf Week	-8.52%

Market Cap	5.68B	Forward P/E	84.61	EPS next Y	0.30	Insider Trans	-3.75%	Shs Float	211.88M	Perf Month	-12.97%

Enterprise Value	6.38B	PEG	—	EPS next Q	0.06			Short Float	25.24%	Perf Quarter	-21.52%

Income	-141.00M	P/S	2.20	EPS this Y	-226.91%			Short Ratio	4.41	Perf Half Y	-7.44%

Sales	2.58B	P/B	17.52	EPS next Y	—	ROA	-3.91%	Short Interest	53.47M	Perf YTD	-22.27%

Book/sh	1.44	P/C	6.75	EPS next 5Y	—	ROE	-30.03%	52W High	48.34 -47.79%	Perf Year	-42.71%

Cash/sh	3.74	P/FCF	63.08	EPS past 3/5Y	—	ROIC	-3.73%	52W Low	13.74 83.70%	Perf 3Y	315.13%

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	64.55% 73.58%	Gross Margin	64.68%	Volatility	7.03% 6.30%	Perf 5Y	217.88%

Dividend TTM	—	EV/Sales	2.48	EPS Y/Y TTM	-178.32%	Oper. Margin	-3.59%	ATR (14)	1.91	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	0.87	Sales Y/Y TTM	28.00%	Profit Margin	-5.51%	RSI (14)	37.03	Recom	2.65

Dividend Gr. 3/5Y	—	Current Ratio	0.93	EPS Q/Q	-317.65%	SMA20	-12.11%	Beta	2.50	Target Price	32.17

Payout	0.00%	Debt/Eq	4.77	Sales Q/Q	38.17%	SMA50	-12.57%	Rel Volume	1.00	Prev Close	27.68

Employees	2,442	LT Debt/Eq	4.73	Earnings	Nov 09	SMA200	-6.52%	Avg Volume	10.64M	Price	25.24

IPO Date	Sep 13, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-643.15% 7.77%	Net Debt/EBITDA	—	Volume	10,679,571	Change	-8.81%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-24-26	Reiterated	Truist Securities	Hold	$18 → $32
Aug-11-26	Reiterated	Deutsche Bank	Hold	$25 → $26
Aug-11-26	Reiterated	Needham	Buy	$30 → $42
Aug-11-26	Reiterated	Morgan Stanley	Equal Weight	$21 → $28
Jul-09-26	Reiterated	UBS		$25 → $37
Jul-01-26	Reiterated	Canaccord Genuity	Buy	$32 → $40
Jun-02-26	Reiterated	Leerink Partners	Market Perform	$18 → $25
May-26-26	Reiterated	UBS		$23 → $25
May-22-26	Reiterated	UBS		$18 → $23
May-12-26	Reiterated	Jefferies	Hold	$26 → $25

Latest News· Times ET

Nov-02-26

Nov-02-2605:54PM

HIMS Deadline: HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuitprnewswire.com

03:15PM

HIMS DEADLINE TODAY: ROSEN, A LEADING NATIONAL FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - HIMSnewsfilecorp.com

11:56AM

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Hims (NYSE: HIMS) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026businesswire.com

11:30AM

Can Hims & Hers Stock Rally 50% After This Dip?Yahoo

10:35AM

DEADLINE ALERT for Hims & Hers Health, Inc. (HIMS), Unicycive Therapeutics, Inc. (UNCY), and Papa John's International, Inc. (PZZA): The Law Offices of Frank R. Cruz Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actionsglobenewswire.com

Nov-01-26

Nov-01-2611:46AM

HIMS Deadline in 1 Day: Hims & Hers Health, Inc. (NYSE: HIMS) Class Action Lawsuit Seeks Recovery for Investors; November 2, 2026 Deadline- Contact Kessler Topaz Meltzer & Check, LLPglobenewswire.com

09:30AM

HIMS DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Hims Investors of Securities Class Action Lawsuit Deadline on November 2, 2026newsfilecorp.com

Oct-31-26

Oct-31-2609:02PM

HIMS FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 2 Deadline in Securities Class Action - HIMSglobenewswire.com

08:13PM

HIMS FINAL DEADLINE: ROSEN, A TRUSTED INVESTOR RIGHTS LAW FIRM, Encourages Hims & Hers Health, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 2 Deadline in Securities Class Action - HIMSnewsfilecorp.com

09:02AM

HIMS DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urges Hims & Hers Health, Inc. Investors to Contact the Firm Before November 2ndglobenewswire.com

Oct-30-26

Oct-30-2608:10PM

HIMS FINAL DEADLINE: ROSEN, A TOP-RANKED LAW FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - HIMSnewsfilecorp.com

07:22PM

Hims & Hers Health 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Hims & Hers Health, Inc. - HIMSbusinesswire.com

01:55PM

HIMS 3-DAY DEADLINE ALERT: Hims & Hers Health Investors with Significant Losses Encouraged to Contact Hagens Berman Before Nov. 2, 2026 Deadline in Securities Class Actionprnewswire.com

01:10PM

What Should Hims & Hers Health, Inc. Investors Know After 14.73% Stock Drop? The Law Offices of Frank R.prnewswire.com

12:50PM

Kaplan Fox Urges Investors of Hims & Hers Health, Inc. (NYSE: HIMS) to Contact the Firm Before the Securities Class Action Deadline on November 2, 2026globenewswire.com

Company

Hims & Hers Health, Inc. operates a comprehensive digital health platform that seamlessly links individuals with licensed medical professionals for virtual consultations and ongoing care. Through its user-friendly websites and mobile app, the company delivers a diverse portfolio of health and wellness solutions directly to consumers. This includes access to recurring prescription medications, alongside a wide selection of over-the-counter drugs, devices, cosmetics, and dietary supplements. Its core focus areas are general wellness, sexual health, skincare, and hair care. Specific non-prescription offerings span categories such as: Wellness: encompassing items like vitamin C, melatonin, biotin, and collagen protein supplements. Skincare: including products such as moisturizers, serums, and face washes. Sexual Health: providing essentials like condoms, climax delay sprays and wipes, vibrators, and lubricants. Hair Care: offering specialized shampoos, conditioners, scalp scrubs, and topical treatments like minoxidil. Beyond direct sales, Hims & Hers also distributes health and wellness products via wholesale partnerships. The company's headquarters are located in San Francisco, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019
Total Revenue	2,578	2,348	1,477	872	—	—	—	—
Cost of Goods Sold Incl. D&A	910	614	303	157	—	—	—	—
Gross Profit	1,667	1,733	1,173	715	—	—	—	—
Selling, General and Administrative Excl. Other	1,387	1,192	847	576	—	—	—	—
Research and Development	129	149	79	48	—	—	—	—
Other Operating Expense	244	287	185	120	—	—	—	—
Operating Income	-92	106	62	-29	—	—	—	—
Interest Expense	0	0	0	0	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-71	18	10	8	—	—	—	—
Net Income Before Taxes	-165	124	72	-22	—	—	—	—
Income Taxes	-21	-4	-54	2	—	—	—	—
Consolidated Net Income	-141	128	126	-24	—	—	—	—
Net Income From Continuing Operations	-141	128	126	-24	—	—	—	—
Net Income	-141	128	126	-24	—	—	—	—
EPS (Recurring)	-0.61	0.57	0.58	-0.11	—	—	—	—
EPS (Basic, Before Extraordinaries)	-0.61	0.57	0.58	-0.11	—	—	—	—
EPS (Diluted)	-0.63	0.51	0.53	-0.11	—	—	—	—
EBITDA	-77	178	89	-12	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	63.67	45.62	—	—	—	—	—
Price To Sales Ratio	2.27	3.11	3.54	2.13	—	—	—	—
Gross Margin	64.66	73.81	79.42	82.00	—	—	—	—
Operating Margin	-3.57	4.51	4.20	-3.33	—	—	—	—
Net Margin	-5.47	5.45	8.53	-2.75	—	—	—	—
Shares Outstanding	232	225	216	209	—	—	—	—
Market Capitalization	5,856	7,306	5,223	1,860	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Boughton Soleil	Chief Legal Officer	Oct 28 '26	Sale	27.60	3,462	95,551	293,886	Oct 29
Boughton Soleil	Chief Legal Officer	Oct 14 '26	Sale	29.06	3,461	100,577	297,348	Oct 15
Okupe Oluyemi	Chief Financial Officer	Oct 01 '26	Sale	29.70	2,000	59,400	234,527	Oct 02
Boughton Soleil	Chief Legal Officer	Sep 30 '26	Sale	29.17	3,461	100,957	300,809	Oct 02
Okupe Oluyemi	Chief Financial Officer	Sep 22 '26	Option Exercise	5.01	14,000	70,140	265,804	Sep 23
Okupe Oluyemi	Chief Financial Officer	Sep 22 '26	Sale	29.95	29,277	876,846	236,527	Sep 23
Okupe Oluyemi	Chief Financial Officer	Sep 17 '26	Sale	28.82	12,313	354,861	251,804	Sep 18
Boughton Soleil	Chief Legal Officer	Sep 16 '26	Sale	27.86	6,236	173,735	304,270	Sep 17
Chi Michael	Chief Operating Officer	Sep 15 '26	Sale	28.39	14,027	398,227	456,660	Sep 17
Elshenawy Mohamed	CTO	Sep 15 '26	Sale	28.39	7,954	225,814	185,556	Sep 17
Boughton Soleil	Chief Legal Officer	Sep 02 '26	Sale	28.33	3,458	97,965	310,506	Sep 03
Okupe Oluyemi	Chief Financial Officer	Aug 19 '26	Sale	29.99	4,938	148,111	264,117	Aug 20
Okupe Oluyemi	Chief Financial Officer	Aug 19 '26	Option Exercise	5.01	4,938	24,739	269,055	Aug 20
Boughton Soleil	Chief Legal Officer	Aug 19 '26	Sale	27.55	25,111	691,808	313,964	Aug 20
Autor Deborah M.	Chief Policy Officer	Aug 18 '26	Sale	27.85	16,773	467,128	48,961	Aug 20

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.